Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Cipla Limited manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct art units, reflecting a focused but not entirely singular technical scope. The portfolio involves 3 distinct examiners, meaning each pending action is overseen by a different individual, which promotes a variety of perspectives during the examination process.
SZNAIDMAN, MARCOS L is the busiest examiner, currently responsible for 1 pending office action. The presence of 3 distinct examiners for the 3 pending office actions suggests a decentralized prosecution environment where no single examiner has a controlling influence. This requires the applicant to tailor their arguments to the specific tendencies of 3 different officials.
The busiest examiner, SZNAIDMAN, MARCOS L, handles only 1 pending office action, which is consistent with the overall distribution of the portfolio. Managing 2 distinct art units within the Biotechnology & Pharmaceuticals field means the practitioner must be aware of the different examination speeds and styles prevalent in those specific groups. The 3 distinct examiners ensure that each case is treated as an independent matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041328 | PHYTONADIONE COMPOSITIONS | CORNET, JEAN P | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041328 | PHYTONADIONE COMPOSITIONS | CORNET, JEAN P | 9d |
| 18691556 | SOLID STATE FORMS OF RELUGOLIX | SZNAIDMAN, MARCOS L | — |
| 18548691 | SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691556 | SOLID STATE FORMS OF RELUGOLIX | SZNAIDMAN, MARCOS L | 1628 | §112 | Final Rejection | — | Pending | Mar 13, 2024 |
| 18548691 | SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF | VALLE, ERNESTO | 1623 | §112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18041328 | PHYTONADIONE COMPOSITIONS | CORNET, JEAN P | 1628 | §102§103 | Final Rejection | 9d | Pending | Feb 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial